Home › Funds › Octagon Capital Advisors LP › ERAS
Octagon Capital Advisors LP position in ERAS
ERASCA INC · Health Care
Octagon Capital Advisors LP reported holding 720,000 shares of ERAS (ERASCA INC) in its Q3 2026 13F filing — a position valued at US$10.6M, representing 1.41% of its reported portfolio and ranking #16 among its reported holdings. Octagon Capital Advisors LP has disclosed ERAS holdings in 5 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Octagon Capital Advisors LP's ERAS position evolved
Octagon Capital Advisors LP first disclosed a stake in ERAS in Q4 2024 at 5,136,795 shares (US$12.9M). The position peaked in Q2 2026 at 1,255,000 shares, worth US$23.0M. Across 5 filings, Octagon Capital Advisors LP increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 720,000 shares valued at US$10.6M — a reduction of -535,000 shares quarter over quarter.. Notable position changes include a 86% trim in Q2 2025 (shares rose 72% over the following quarter), a 43% trim in Q3 2026 (shares rose 3% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 5.14M | $12.89M | New |
| Q1 2025 | 5.14M | $7.04M | Hold |
| Q2 2025 | 700.00K | $889.00K | Reduce |
| Q2 2026 | 1.25M | $22.99M | New |
| Q3 2026 | 720.00K | $10.56M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ERAS and 13F data
ERAS (ERASCA INC) is a Health Care company. 63 other funds we track also report a position in ERAS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$432.1M), RTW INVESTMENTS, LP (US$329.1M), Venrock Adviser, LLC (US$294.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ERAS
- Frazier Life Sciences Management, L.P. 29.48M sh · $432.11M · Q3 2026
- RTW INVESTMENTS, LP 22.45M sh · $329.07M · Q3 2026
- Venrock Adviser, LLC 20.09M sh · $294.52M · Q3 2026
- Siren, L.L.C. 13.20M sh · $193.48M · Q3 2026
- Paradigm Biocapital Advisors LP 8.00M sh · $117.25M · Q3 2026
- ARCH Venture Management, LLC 7.09M sh · $103.96M · Q3 2026
- Affinity Asset Advisors, LLC 5.59M sh · $81.96M · Q3 2026
- Soleus Capital Management, L.P. 5.11M sh · $74.94M · Q3 2026
- Cormorant Asset Management, LP 5.00M sh · $73.30M · Q3 2026
- Vivo Capital, LLC 4.02M sh · $58.94M · Q3 2026
- EcoR1 Capital, LLC 2.95M sh · $43.25M · Q3 2026
- SAMLYN CAPITAL, LLC 2.54M sh · $37.29M · Q3 2026
More on Octagon Capital Advisors LP
FAQ
How long has Octagon Capital Advisors LP held ERAS?
Octagon Capital Advisors LP has disclosed ERAS holdings in 5 of the last 8 reported quarters, going back to Q4 2024.
What is Octagon Capital Advisors LP's current position in ERAS?
As of Q3 2026, Octagon Capital Advisors LP holds 720.00K shares of ERAS (ERASCA INC), valued at $10.56M, representing 1.41% of its reported portfolio and ranking #16.
Has Octagon Capital Advisors LP been buying or selling ERAS?
In the latest 13F filing (Q3 2026), Octagon Capital Advisors LP reduced its position in ERAS. The position peaked in Q2 2026 at 1.25M shares.
Which other funds hold ERAS?
Other major institutional holders of ERAS include Frazier Life Sciences Management, L.P., RTW INVESTMENTS, LP, Venrock Adviser, LLC, among 63 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.